P5-Mouse Phenotyping
P5-小鼠表型分析
基本信息
- 批准号:8080387
- 负责人:
- 金额:$ 23.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-06-01 至 2012-05-31
- 项目状态:已结题
- 来源:
- 关键词:AcousticsAcute Erythroblastic LeukemiaAddressAffectAgeAge-MonthsAgonistAmphetaminesAnimal ModelAnimalsAnisotropyAnteriorAntipsychotic AgentsAnxietyApomorphineAutopsyBehaviorBehavioralBiological ModelsBoxingBrainBrain regionCellsCellular biologyCognitiveCollaborationsComplexConsultationsCorpus striatum structureCoupledCyclic NucleotidesDevelopmentDopamineERBB2 geneEquilibriumEsthesiaEthylnitrosoureaEtiologyEvaluationEvolutionExposure toG-substrateGTP-Binding ProteinsGelsolinGene AbnormalityGene ExpressionGene ProteinsGenesGeneticGlutamate DecarboxylaseGlutamate ReceptorGrantHaloperidolHomologous GeneImageIndium-111IndividualKetamineKnock-outKnockout MiceLearningLocomotionMemoryMessenger RNAModelingModificationMolecularMotorMotor ActivityMusMutationMyelinMyelin Associated GlycoproteinMyelin ProteinsN-Methyl-D-Aspartate ReceptorsNeuroanatomyNeuronsOligodendrogliaParahippocampal GyrusPeripheralPersonsPharmaceutical PreparationsPhenotypePlayProteinsReagentReceptor SignalingReflex actionRegulationReportingResourcesRodent ModelRoleSchizophreniaScreening procedureSignal TransductionSocial InteractionSpecificitySpecimenStagingStructureSuperior temporal gyrusSynapsesSynapsin ITechniquesTestingTimeTransferrinUpdateViral OncogeneWorkbasebehavior influencebehavior testbrain tissuecingulate cortexgenetic associationin vivointerestlaser capture microdissectionmeetingsmolecular phenotypemouse modelmyelinationneurochemistryneuroimagingoligodendrocyte precursoroverexpressionphosphoric diester hydrolasepostsynaptic density proteinprecursor cellprepulse inhibitionprotein expressionputamenresearch studyresponsestereotypytranscription factorwhite matterworking groupyoung adult
项目摘要
This project is dedicated to the development and characterization of mouse model systems that best reflect
the myelin and oligodendrocyte related (OMR) gene expression deficits in persons with schizophrenia.
Several different genetically modified mouse model systems will be evaluated (e.g., Quaking, MAG,
PTPRZ1, and Olig2. Each of these mouse model systems will be screened for deficits in the expression of
OMR genes using a panel of OMR genes that we have shown to be differentially affected in schizophrenia.
Those that evidence gene expression deficits on at least 3 OMR genes known to be affected in
schizophrenia will then be assessed for behavioral deficits. The behavioral phenotyping test battery will
include screening tests of simple (e.g., reflexes, locomotion, balance, sensation) as well as complex
(learning, memory, startle, prepulse inhibition of startle, social interaction, anxiety) behaviors. Coupled with
these purely behavioral tests will be pharmacological probes to ascertain whether pharmacological profiles
commonly viewed as prototypical for rodent models of schizophrenia are also evidenced by the OMR gene
deficient mice. Once "best-fit" model systems have been identified, they will be studied longitudinally to
ascertain the evolution of gene expression and behavioral deficits from 3 months of age through to 18
months of age. In addition, laser capture microdissection techniques will be employed to investigate gene
expression in identified cell groups. In collaboration with Project 1, the "best-fit" mouse model system will be
systematically imaged by DTI in vivo at ages corresponding to those for behavioral testing. In collaboration
with Project 3, brain tissue specimens from additional mice will be studied for changes in oligodendroglial
proliferation, differentiation and survival. Significant progress has already been made in this regard. All of
the behavioral test paradigms have been piloted and parameters have been optimized for use in mice in our
phenotyping facility (results and descriptions appended). Three of the 4 animal model systems proposed for
use (Quaking, Olig2, and MAG) have been obtained. Some studies have already been completed in these
mice and colonies have been established to enable more large scale studies.
该项目致力于开发和表征最能反映
精神分裂症患者的髓磷脂和少突胶质细胞相关(OMR)基因表达缺陷。
将评估几种不同的转基因小鼠模型系统(例如,Quaking、MAG、
PTPRZ1 和 Olig2。将筛选每个小鼠模型系统的表达缺陷
OMR 基因使用一组 OMR 基因,我们已证明这些基因在精神分裂症中受到不同程度的影响。
那些证明至少 3 个已知受影响的 OMR 基因存在基因表达缺陷的基因
然后将评估精神分裂症的行为缺陷。行为表型测试电池将
包括简单(例如反射、运动、平衡、感觉)和复杂的筛选测试
(学习、记忆、惊吓、惊吓的前脉冲抑制、社交互动、焦虑)行为。加上
这些纯粹的行为测试将是药理学探针,以确定药理学特征是否
OMR 基因也证明了通常被视为精神分裂症啮齿动物模型的原型
缺乏的老鼠。一旦确定了“最适合”的模型系统,将对它们进行纵向研究,以
确定从 3 个月大到 18 岁的基因表达和行为缺陷的演变
月龄。此外,激光捕获显微切割技术将用于研究基因
在确定的细胞群中表达。与项目 1 合作,“最适合”的小鼠模型系统将
在与行为测试年龄相对应的年龄通过 DTI 进行体内系统成像。合作中
在项目 3 中,将研究来自其他小鼠的脑组织标本中少突胶质细胞的变化
增殖、分化和存活。在这方面已经取得了重大进展。所有的
行为测试范式已经进行了试点,参数也已经过优化,可用于我们的小鼠
表型分析设施(结果和说明附后)。提议的 4 个动物模型系统中的 3 个
已获得使用(Quaking、Olig2 和 MAG)。这些方面的一些研究已经完成
小鼠和群体的建立是为了进行更大规模的研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
VAHRAM HAROUTUNIAN其他文献
VAHRAM HAROUTUNIAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('VAHRAM HAROUTUNIAN', 18)}}的其他基金
The adaptive-innate immune interactome across multiple tissues in Alzheimer's disease
阿尔茨海默病跨多个组织的适应性先天免疫相互作用组
- 批准号:
10662733 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
NIH BRAIN AND TISSUE RESPOSITORY (NBTR)
美国国立卫生研究院 (NIH) 脑和组织存储库 (NBTR)
- 批准号:
10916989 - 财政年份:2023
- 资助金额:
$ 23.25万 - 项目类别:
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
FSH 升高——阿尔茨海默病性别差异的驱动因素
- 批准号:
10685326 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
FSH 升高——阿尔茨海默病性别差异的驱动因素
- 批准号:
10302046 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Single-nucleus transcriptome profiling across multiple brain regions in Parkinson's Disease
帕金森病多个脑区的单核转录组分析
- 批准号:
10372330 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
FSH 升高——阿尔茨海默病性别差异的驱动因素
- 批准号:
10685326 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
Elevated FSH - A Driver for Sex Differences in Alzheimer's Disease
FSH 升高——阿尔茨海默病性别差异的驱动因素
- 批准号:
10495197 - 财政年份:2021
- 资助金额:
$ 23.25万 - 项目类别:
THE PURPOSE OF THIS CONTRACT IS TO ESTABLISH COLLECTION SITES(S) (I.E., THE NIH BRAIN AND TISSUE REPOSITORY (NBTR)) TO PROVIDE SERVICES THAT WILL ACTIVELY ACQUIRE, RECEIVE, PROCESS, STORE, CURATE, PRE
本合同的目的是建立收集站点(即 NIH 大脑和组织存储库 (NBTR)),以提供积极获取、接收、处理、存储、整理、预检的服务
- 批准号:
10473437 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
THE PURPOSE OF THIS CONTRACT IS TO ESTABLISH COLLECTION SITES(S) (I.E., THE NIH BRAIN AND TISSUE REPOSITORY (NBTR)) TO PROVIDE SERVICES THAT WILL ACTIVELY ACQUIRE, RECEIVE, PROCESS, STORE, CURATE, PRE
本合同的目的是建立收集站点(即 NIH 大脑和组织存储库 (NBTR)),以提供积极获取、接收、处理、存储、整理、预检的服务
- 批准号:
10685914 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
Understanding the protective and neuroinflammatory role of human brain immune cells in Alzheimer Disease
了解人脑免疫细胞在阿尔茨海默病中的保护和神经炎症作用
- 批准号:
10362719 - 财政年份:2020
- 资助金额:
$ 23.25万 - 项目类别:
相似国自然基金
促红细胞生成素介导儿童急性淋巴细胞白血病骨质破坏的作用及其机制研究
- 批准号:81800185
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目